Amneal Reports Second Quarter 2025 Financial Results

‒ ‒ Adjusted EBITDA of $184 million; Adjusted Diluted EPS of $0.25 ‒ ‒ Raising 2025 Full Year Guidance ‒ ‒ Full Debt Refinancing Reduces Interest Cost and Extends Maturities to 2032 ‒ BRIDGEWATER, N.J., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) ("Amneal" or the "Company") today announced its results for the second quarter ended June 30, 2025. "Amneal delivered another quarter of solid growth, strong profitability, and we are pleased to raise our full year 2025 guidance. T ...